Dogwood Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Dogwood Therapeutics, Inc. (DWTX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$11.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-14
- Dogwood Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$11.53M.
- Dogwood Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$4.99M.
- Dogwood Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$3.78M.
- Dogwood Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$15.74M.
- Dogwood Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$35.51M.
- Dogwood Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$12.86M.
- Dogwood Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$5.30M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.53M 10-Q · filed 2026-08-14 | -$16.52M 10-Q · filed 2026-08-14 | -$20.30M derived: sum of 3 quarters · filed 2026-08-14 | -$36.04M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$4.99M 10-Q · filed 2026-05-15 | -$8.77M derived: sum of 2 quarters · filed 2026-05-15 | -$24.51M derived: sum of 3 quarters · filed 2026-05-15 | -$28.32M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$19.53M derived: sum of 2 quarters · filed 2026-03-18 | -$23.33M derived: sum of 3 quarters · filed 2026-08-14 | -$35.51M 10-K · filed 2026-03-18 |
| 2025-09-30 | -$15.74M 10-Q · filed 2025-11-07 | -$19.55M derived: sum of 2 quarters · filed 2026-08-14 | -$31.73M 10-Q · filed 2025-11-07 | -$39.98M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$3.81M 10-Q · filed 2026-08-14 | -$15.99M 10-Q · filed 2026-08-14 | -$24.23M derived: sum of 3 quarters · filed 2026-08-14 | -$26.51M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$12.18M 10-Q · filed 2026-05-15 | -$20.42M derived: sum of 2 quarters · filed 2026-05-15 | -$22.70M derived: sum of 3 quarters · filed 2026-05-15 | -$23.75M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$8.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$10.52M derived: sum of 2 quarters · filed 2026-03-18 | -$11.57M derived: sum of 3 quarters · filed 2026-03-18 | -$12.86M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$2.28M 10-Q · filed 2025-11-07 | -$3.33M derived: sum of 2 quarters · filed 2025-11-07 | -$4.62M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | -$1.05M 10-Q · filed 2025-08-13 | -$2.34M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$1.29M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | -$5.30M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |